Department of Immunology

Jessica Hamerman, Ph.D.

MEMBER, BENAROYA RESEARCH INSTITUTE AND AFFILIATE PROFESSOR, IMMUNOLOGY

Jessica Hamerman received her B.S. in Biological Sciences from Stanford University and her Ph.D. in Immunology from the University of Washington. She then pursued postdoctoral studies at the University of California, San Francisco before joining the Benaroya Research Institute Immunology Program.

CONTACT

Benaroya Research Institute
at Virginia Mason
1201 Ninth Avenue
Seattle, WA 98101-2795
Phone: 206-287-1077
Fax: 206-233-7543

RESEARCH AREAS

Innate Immunity
Monocytes, Macrophages, Dendritic Cells
Autoimmunity
Infectious diseases

LAB MEMBERS

Graduate Students
Natalie Thulin, nthulin@uw.edu
Hayley Waterman, hayleyw@uw.edu

Postdoctoral Fellows
Susan Canny, scanny@benaroyaresearch.org
Susana Orozco, sorozco@benaroyaresearch.org
Allison O’Rourke, aorourke@benaroyaresearch.org

Laboratory Staff
Griff Gessay, Research Technician,
ggessay@benaroyaresearch.org
Minjian Ni, Staff Scientist, mni@benaroyaresearch.org,
Noah Biru, Lab Aide, nbiru@benaroyaresearch.org

LAB

Benaroya Research

PUBMED

Jessica Hamerman on PubMed

RESEARCH

Research in the Hamerman Lab is focused on understanding the process of inflammation and how it is regulated by specific subsets of myeloid cells. We study monocytes and macrophages, initiators of inflammation, and dendritic cells (DCs), initiators of adaptive immunity. The lab investigates molecular mechanisms by which these cells initiate inflammatory and immune responses after recognition of pathogens, studying both positive and negative regulatory pathways. We also investigate how myeloid cells differentiate during homeostasis and inflammation. Our goal is to understand how monocytes, macrophages and DCs respond during infection and inflammation, and how this promotes clearance of pathogens and susceptibility to inflammatory and autoimmune disease. We currently focus on myeloid responses in a several diseases, including systemic lupus erythematosus and macrophage activation syndrome, and infections, including malaria and respiratory viruses.

PUBLICATIONS

  1. Carpentier SJ, Ni M, Duggan JM, James RG, Cookson BT, Hamerman JA. The signaling adaptor BCAP inhibits NLRP3 and NLRC4 inflammasome activation in macrophages through interactions with Flightless-1. Science Signaling. 2019 May 14;12(581). pii:eaaau0615. PMID: 31088976
  2. Chu T, Ni M, Chen C, Akilesh R, Hamerman JA. Cutting Edge: BCAP Promotes Lupus-like Disease and TLR-Mediated Type I IFN Induction in Plasmacytoid Dendritic Cells. J Immunol. 2019 May 1;202(9):2529-2534. doi: 10.4049/jimmunol.1801267. PMID: 30936294
  3. Akilesh HM, Buechler MB, Duggan JM, Hahn WO, Matta B, Sun X, Gessay G, Whalen E, Mason M, Presnell SR, Keith B. Elkon, Lacy-Hulbert A, Barnes BJ, Pepper M, Hamerman JA. Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes. Science. 2019 Jan 11;363(6423). pii: eaao5213. doi: 10.1126/science.aao5213. PMID: 30630901 | PMC6413693
  4. Singh MD, Ni M, Sullivan JM, Hamerman JA, Campbell DJ. B cell adaptor for PI3-kinase (BCAP) modulates CD8+ effector and memory T cell differentiation. J Exp Med. 2018 Sep 3;215(9):2429-2443. doi: 10.1084/jem.20171820. PMID: 30093532 | PMC6122975
  5. Duggan JM, Buechler MB, Olson RM, Hohl TM, Hamerman JA. BCAP inhibits proliferation and differentiation of myeloid progenitors in the steady state and during demand situations. Blood. 2017 Mar 16;129(11):1503-1513. doi: 10.1182/blood-2016-06-719823. PMID: 28087538 | PMC5356451
  6. Buechler MB, Akilesh HM, Hamerman JA. Cutting Edge: Direct Sensing of TLR7 Ligands and Type I IFN by the Common Myeloid Progenitor Promotes mTOR/PI3K-Dependent Emergency Myelopoiesis. J Immunol. 2016 Oct 1;197(7):2577-82. doi: 10.4049/jimmunol.1600813. PMID: 27566824 | PMC5026975
  7. Hamerman JA, Pottle J, Ni M, He Y, Zhang ZY, Buckner JH. Negative regulation of TLR signaling in myeloid cells–implications for autoimmune diseases. Immunol Rev. 2016 Jan;269(1):212-27. doi: 10.1111/imr.12381. PMID: 26683155 | PMC4703580
  8. Buechler MB, Gessay GM, Srivastava S, Campbell DJ, Hamerman JA. Hematopoietic and nonhematopoietic cells promote Type I interferon- and TLR7-dependent monocytosis during low-dose LCMV infection. Eur J Immunol. 2015 Nov;45(11):3064-72. doi: 10.1002/eji.201445331. PMID: 26289159 | PMC4675142
  9. Buechler MB, Teal TH, Elkon KB, Hamerman JA. Cutting edge: Type I IFN drives emergency myelopoiesis and peripheral myeloid expansion during chronic TLR7 signaling. J Immunol. 2013 Feb 1;190(3):886-91. doi: 10.4049/jimmunol.1202739. PMID: 23303674 | PMC3552021
  10. Ni M, MacFarlane AW, Toft M, Lowell CA, Campbell KS, Hamerman JA. B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K. Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):267-72. doi: 10.1073/pnas.1111957108. PMID: 22187458 | PMC3252908
Print Friendly, PDF & EmailPrintFriendly